Sign in to NCBI

Display Settings:

Format

Send to:

Choose Destination
Accession: PRJEB11252 ID: 341649

Irritable bowel syndrome-related differences in the fecal microbiome after the rifaximin treatment

Background. Irritable bowel syndrome (IBS) is a chronic functional disorder, the development and maintenance of which may be linked, directly and indirectly, to intestinal dysbiosis. More...
AccessionPRJEB11252; ENA-SUBMISSION: ERA518979
ScopeMonoisolate
PublicationsZeber-Lubecka N et al., "Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.", Gut Microbes, 2016 Sep 2;7(5):397-413
SubmissionRegistration date: 2-Sep-2016
Centrum Medyczne Ksztalcenia Podyplomowego
Locus Tag PrefixBN2844
Project Data:
Resource NameNumber
of Links
Sequence data
SRA Experiments175
Publications
PubMed1
PMC1
Other datasets
BioSample175
SRA Data Details
ParameterValue
Data volume, Gbases4
Data volume, Mbytes3346

Supplemental Content

Related information

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI
Support Center